Evidence
Explor Target Antitumor Ther. 2023;4(4):556-568. doi: 10.37349/etat.2023.00152. Epub 2023 Aug 24.
ABSTRACT
Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. Meanwhile, immunotherapy with immune checkpoint inhibitors has been established to be a favorable therapeutic possibility for advanced HCC. Although curative opportunities for advanced HCC are restricted, the immune checkpoint immunotherapy has developed as the main choice for treating HCC. However, patients with metabolic-associated fatty liver disease (MAFLD)-linked HCC might be less likely to benefit from the immunotherapy alone. The limitation of the effect of the immunotherapy might be owing to the impaired T cell activation in MAFLD patients, which could be well explained by a dysfunctional gut-liver axis. Gut microbiota and their metabolites including several bile acids could contribute to modulating the responses of the immune checkpoint immunotherapy. Roles of gut microbiota in the development of cancers have expected great interest in the latest studies. Here, an interplay between the gut and liver has been presented, which might suggest to affect the efficacy of immune checkpoint immunotherapy against HCC.
PMID:37720344 | PMC:PMC10501893 | DOI:10.37349/etat.2023.00152
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment
- Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
- Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer
- Pivotal role of intestinal cholesterol and nuclear receptor LXR in metabolic liver steatohepatitis and hepatocarcinoma
- Role of Culinary Indian Spices in the Regulation of TGF-β Signaling Pathway in Inflammation-Induced Liver Cancer
- Role of Culinary Indian Spices in the Regulation of TGF-β Signaling Pathway in Inflammation-Induced Liver Cancer
- TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation
- Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice
- Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes
- Critical role of the gut microbiota in immune responses and cancer immunotherapy
- Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia
- Substitutions of saturated fat intakes with other macronutrients and foods and risk of NAFLD cirrhosis and all-cause hepatocellular carcinoma: a prospective cohort study
- Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy
- Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy
- FGL1 and FGL2: emerging regulators of liver health and disease
- Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma
- Diet, lifestyle factors, comorbidities, and hepatocellular carcinoma risk in a middle eastern country: a case-control study
- Potential Role of MAP3K14 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis and Validation
- Potential Role of MAP3K14 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis and Validation
- Epigenetic regulation of hepatocellular carcinoma progression: microRNAs as therapeutic, diagnostic and prognostic factors
- Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma
- FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma
- Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH
- MRI radiomics based on deep learning automated segmentation to predict early recurrence of hepatocellular carcinoma
- Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells
- The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma
- Development of an individualized model for predicting postoperative delirium in elderly patients with hepatocellular carcinoma
- Transplant and non-transplant HCC patients at a single institution
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade
- Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- IFRD1 promotes tumor cells "low-cost" survival under glutamine starvation via inhibiting histone H1.0 nucleophagy
- Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- Outcomes and Recurrence Rate of Esophageal Varices after Endoscopic Treatment in Patients with Alcoholic Cirrhosis and Viral Cirrhosis
- Postoperative Lenvatinib plus PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with MVI (BCLC 0-A): A Propensity Score Matching Analysis
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Prognostic analysis of sex and age in hepatocellular carcinoma: a SEER study
- Imaging-based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids
- Role of the angiopoietin-like protein family in the progression of NAFLD
- The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review
- Microsatellite Instability, Mismatch Repair, and Tumor Mutation Burden in Lung Cancer
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
Evidence Blueprint
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options
- An overview of mouse models of hepatocellular carcinoma
- Gamma Delta T Cells: Role in Immunotherapy of Hepatocellular Carcinoma
- The effect of liver disease on hepatic microenvironment and implications for immune therapy
- METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy
- Real-World Use of Immunotherapy for Hepatocellular Carcinoma
- Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation
- Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
- Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma
- Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology
- Recent advances in the management of hepatocellular carcinoma
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Regulation of Hepatocellular Carcinoma Epithelial-Mesenchymal Transition Mechanism and Targeted Therapeutic Approaches
- The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma
- New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow
- Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis
- Alternative splicing: a bridge connecting NAFLD and HCC
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma
- Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma
- Phytochemicals as Potential Lead Molecules against Hepatocellular Carcinoma
- Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma
- Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Loss of cis-PTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Pan-Cancer Profiling and Digital Pathology Analysis Reveal Negative Prognostic Biomarker ZPR1 Associated with Immune Infiltration and Treatment Response in Hepatocellular Carcinoma
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
- The Current Landscape of Therapies for Hepatocellular Carcinoma
- Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States
- A Rare Type of Hepatocellular Carcinoma Presenting With Cardiac Thrombus
- Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma
- Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis
- N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas
- Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma
- Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
- Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma
- Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid
- Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer
- Prognostic and immune roles of UROC1 in human cancers: from mechanism exploration of NAFLD and HCC to pan-cancer analysis
- Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma
- Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma
- Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score
- Pivotal role of intestinal cholesterol and nuclear receptor LXR in metabolic liver steatohepatitis and hepatocarcinoma
- Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: the Multi-center Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study
- Chest wall mass as a sign of ignored hepatocellular carcinoma in an alcoholic cirrhotic patient: a case report
- A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD
- Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36
- Role of Culinary Indian Spices in the Regulation of TGF-β Signaling Pathway in Inflammation-Induced Liver Cancer
- Role of Culinary Indian Spices in the Regulation of TGF-β Signaling Pathway in Inflammation-Induced Liver Cancer
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Analysis of genetic factors associated with fatty liver disease-related hepatocellular carcinoma
- TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation
- Values of ATX in predicting disease progression in patients with PBC and PBC related HCC
- Distinct Morphological and Molecular Profiles of NAFLD and NAFLD-associated HCC Revealed by Immunohistochemistry and MicroRNA Analysis
- A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma
- Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor